Skip to main content

Table 2 Follow-up antitumor therapy after confirmation of tumor recurrence in patients who received adjuvant TACE or not

From: Efficacy of adjuvant TACE on the prognosis of patients with HCC after hepatectomy: a multicenter propensity score matching from China

Anti-tumor therapy

Before PSM

After PSM

Adjuvant TACE

P

Adjuvant TACE

P

No (n = 275)

Yes (n = 274)

No (n = 255)

Yes (n = 197)

Liver transplantion

4

12

0.037

4

11

0.017

Re-hepatectomy

10

18

0.103

10

17

0.036

Local ablation

111

147

< 0.001

105

112

0.001

TACE

86

42

< 0.001

79

22

< 0.001

chemoradiotherapy

15

8

0.155

14

5

0.125

immunotargeted therapy

49

47

0.954

43

30

0.668

  1. TACE, Transarterial chemoembolization
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us